Pulmonary Arterial Hypertension Market Forecast to 2028

Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)

Report Code : TIPRE00005221 | Region : Global | Industry : Pharmaceuticals | Published Date : 02/Jan/2023

The pulmonary arterial hypertension market is expected to grow from US$ 7,369.89 million in 2021 to US$ 10,889.08 million by 2028; it is estimated to grow at a CAGR of 5.8% from 2022 to 2028. The market growth is attributed to the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs. However, the side effects of drugs used to treat pulmonary arterial hypertension hamper the market growth.

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder caused due to high blood pressure (hypertension) in the arteries of the lungs. The increased pressure in the vessels may be caused by an obstruction in the small arteries in the lung for various reasons. The exact cause of PAH is unknown and although treatable; there is no permanent cure for the disease. PAH usually affects women between the age of 30–60 years..

Patent expiry permits generic drugs to penetrate the pulmonary arterial hypertension market and diversify product offerings. Over the next seven–eight years till 2030, the patented products are expected to go off-patent. This would provide an enormous opportunity for generic formulation companies in the coming years. AMBRISENTAN + TADALAFIL drug by Gilead Sciences, Inc. is used to treat PAH, and its patent will be expired by December 11, 2027. Many pharma companies are already working to develop the generic version of patented products, finds Care Ratings. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to open an opportunity for generic drug manufacturers to enter a new market during the forecast period.

Moreover, over the past 20 years, the arrival of 14 FDA-approved therapies for treating PAH is seen as a major feat considering that this disease affects a small population. The key to success in developing PAH therapies has been the immense advances in understanding the genetic and molecular mechanisms that drive the pathogenesis of the disease. With the growing awareness, the treatment strategies will continue to evolve and diversify from the current paradigm focused on vasoconstriction. Clinical trials are exploring the clinical efficacy of novel delivery devices and their utility in other forms of pulmonary hypertension and combination therapies. This will be the standard for clinical trials in the future.

Route of Administration-Based Insights

Based on route of administration, the pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. The oral segment held the largest pulmonary arterial hypertension market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Orally administered agents used for the treatment of symptomatic, moderate-to-severe PAH include sildenafil and the endothelin (ET) receptor antagonists (ERAs), bosentan and sitaxentan (sitaxsentan), and abrisentan oral ET(A) receptor-selective ERA, with higher ET receptor affinity than bosentan. Moreover, new oral drugs for treating PAH include macitentan, riociguat, and treprostinil. Ambrisentan is an endothelin receptor antagonist indicated for treating PAH; WHO Group 1 and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability..

The pulmonary arterial hypertension market in North America held the largest share in the forecast period. The market growth in the region is attributed to the high prevalence of pulmonary arterial hypertension and initiatives by the government and manufacturers. The US pulmonary arterial hypertension market holds a significant share of the regional market. The prevalence of PAH in the US is much higher, although it is a rare disease. According to the American Lung Association, PAH is a rare and progressive disorder that accounts for about 500–1,000 new cases being diagnosed each year in the US. Additionally, as per the same source, ~15–20% of PAH patients have heritable PAH caused by genetic mutations.

Further, manufacturers undergo various initiatives to provide information and resources to healthcare practitioners, fueling the market growth. The PAH Initiative supported by United Therapeutics provides resources and information to assist healthcare providers in treating patients affected by PAH. In addition, the United States Pulmonary Hypertension Scientific Registry was established as the first US PAH patient registry to investigate genetic information, reproductive histories, and environmental exposure data in a patient population. Thus, the rising cases of PAH diagnosed each year and initiatives undertaken by manufacturers fuel the demand for pulmonary arterial hypertension drugs and other treatment methods, further bolstering the pulmonary arterial hypertension market growth in the US.

Canada holds the second-largest share of the pulmonary arterial hypertension market in North America. Canada has a high prevalence of pulmonary arterial hypertension. According to the PHA Canada, it is estimated that ~10,000 population in the country are affected by pulmonary hypertension (PH), but ~5,000 have been diagnosed with it. A limited number of treatments are approved in Canada to slow the progression of PH and alleviate symptoms. Over the last two decades, only 10 PH-specific medical treatments have been approved in Canada for treating PAH. However, the centers specializing in treating PAH in adults and children are located across the country. Additionally, a study (2022) published in European Respiratory Journal reported that the 1-, 3- and 5-year survival rates in the Canadian PAH cohort were 89.2%, 75.6%, and 56.0%, respectively. Thus, PAH patients in Canada are reported to have a high death rate in the long term.

The World Health Organization (WHO), US Food and Drug Administration (FDA), and National Organization for Rare Disorders (NORD) are among the primary and secondary sources referred to while preparing the report on the pulmonary arterial hypertension market.

Availability of Generics at Affordable Costs Due to Growing Patent Expiration offers Opportunity in Pulmonary Arterial Hypertension Market

According to our new research study on "Pulmonary Arterial Hypertension Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Drug, Type, Route of Administration, and Distribution Channel," the market was valued at US$ 7,369.89 million in 2021 and is projected to reach US$ 10,889.08 million by 2028; it is expected to grow at a CAGR of 5.8% from 2022 to 2028. The report highlights trends prevailing in the market and drivers and restraints pertaining to the pulmonary arterial hypertension market growth.

Patent expiry permits generic drugs to penetrate the market and diversify product offerings. Over the next seven–eight years till 2030, the patented products are expected to go off-patent. This would provide an enormous opportunity for generic formulation companies in the coming years. Many pharma companies are already working to develop the generic version of patented products, finds Care Ratings. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to open up an opportunity for generic drug manufacturers to enter a new market.

Table 1. Drug Patents Expiration Data

Patent Company Ingredient Treatment Expiration Date

US9604901 United Therapeutics Corp TREPROSTINIL Pulmonary Arterial Hypertension December 15, 2028

US9593066 United Therapeutics Corp TREPROSTINIL Pulmonary Arterial Hypertension December 15, 2028

US7205302 Actelion Pharmaceuticals SELEXIPAG Pulmonary Arterial Hypertension October 31, 2026

US8791122 Actelion Pharmaceuticals SELEXIPAG Pulmonary Arterial Hypertension August 1, 2030

US8377933 Gilead Colorado, Inc. AMBRISENTAN + TADALAFIL Pulmonary Arterial Hypertension December 11, 2027

US9474752 Gilead Sciences, Inc. AMBRISENTAN + TADALAFIL Pulmonary Arterial Hypertension December 11, 2027

US9549926 Gilead Sciences, Inc. AMBRISENTAN + TADALAFIL Pulmonary Arterial Hypertension October 14, 2031

.

Thus, the growing patent expiration will offer lucrative opportunities for the global pulmonary arterial hypertension market expansion in the future.

North America held the largest share of the pulmonary arterial hypertension market in 2021. The market in North America is expected to grow in the coming years due to the increasing health expenditure, high pulmonary arterial hypertension prevalence, initiatives by government and manufacturers, and major market players’ presence in the US.

The pulmonary arterial hypertension market in the US was valued at US$ 1,970.59 million in 2021 and is projected to reach US$ 3,019.55 million by 2028, at a CAGR of 6.3% during 2021–2028. In the country, the rising cases of PAH diagnosed each year and initiatives undertaken by drug manufacturers are fueling the demand for pulmonary arterial hypertension drugs and other treatment methods.

The pulmonary arterial hypertension market witnessed low demand as patients were unable to take therapies and treatments from healthcare providers during COVID-19 pandemic. However, by 2021, the market has shown recovery as the pandemic had minimal impact on the sales of PAH drugs. Also, major manufacturers reported having a continuous supply of stock for customers.

Johnson & Johnson, Gilead Sciences Inc, United Therapeutics Corp, Bayer AG, Aerami Therapeutics Holdings Inc, Novartis AG, GSK Plc, Teva Pharmaceutical Industries Ltd, Lupin Ltd, and Pfizer Inc are among the leading companies operating in the global pulmonary arterial hypertension market.

The pulmonary arterial hypertension market is segmented on the basis of drug, type, route of administration, distribution channel, and geography. Based on drug, the market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. Based on type, the pulmonary arterial hypertension market is bifurcated into branded and generics. Based on route of administration, the pulmonary arterial hypertension market is divided into oral, intravenous/ subcutaneous, and inhalational. In terms of distribution channel, the pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies.

In terms of geography, the pulmonary arterial hypertension market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Pulmonary Arterial Hypertension Market – By Drugs

1.3.2 Global Pulmonary Arterial Hypertension Market – By Type

1.3.3 Global Pulmonary Arterial Hypertension Market – By Route of Administration

1.3.4 Global Pulmonary Arterial Hypertension Market – By Distribution Channel

1.3.5 Global Pulmonary Arterial Hypertension Market – By Geography

2. Pulmonary Arterial Hypertension Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Pulmonary Arterial Hypertension Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.2.2 Europe PEST Analysis

4.2.3 Asia Pacific PEST Analysis

4.2.4 Middle East and Africa PEST Analysis

4.2.5 South and Central America PEST Analysis

4.3 Experts Opinion

5. Pulmonary Arterial Hypertension Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Incidence of Pulmonary Arterial Hypertension

5.1.2 Rising Approvals of Pulmonary Arterial Hypertension Drugs

5.2 Market Restraints

5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension

5.3 Market Opportunities

5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration

5.3.2 Drugs Patents Expiration Data

5.4 Future Trend

5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension

5.5 Impact analysis

6. Pulmonary Arterial Hypertension Market – Global Analysis

6.1 Global Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis

6.2 Global Pulmonary Arterial Hypertension Market, By Geography - Forecast and Analysis

6.3 Market Positioning of Key Players

7. Global Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Drugs

7.1 Overview

7.2 Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)

7.3 Endothelin Receptor Antagonists (ERAs)

7.3.1 Overview

7.3.2 Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Prostacyclin and Prostacyclin Analogs

7.4.1 Overview

7.4.2 Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

7.5 SGC Stimulators

7.5.1 Overview

7.5.2 SGC Stimulators: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

7.6 Pde-5 Dipsticks

7.6.1 Overview

7.6.2 Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

8. Global Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 – by Type

8.1 Overview

8.2 Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)

8.3 Branded

8.3.1 Overview

8.3.2 Branded: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Generics

8.4.1 Overview

8.4.2 Generics: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

9. Global Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Route of Administration

9.1 Overview

9.2 Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)

9.3 Oral

9.3.1 Overview

9.3.2 Oral: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Intravenous/ Subcutaneous

9.4.1 Overview

9.4.2 Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

9.5 Inhalational

9.5.1 Overview

9.5.2 Inhalational: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10. Global Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Distribution Channel

10.1 Overview

10.2 Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)

10.3 Hospital Pharmacies and Clinics

10.3.1 Overview

10.3.2 Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10.4 Online Pharmacies

10.4.1 Overview

10.4.2 Online Pharmacies: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10.5 Retail Pharmacies

10.5.1 Overview

10.5.2 Retail Pharmacies: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11. Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – Geographic Analysis

11.1 North America: Pulmonary Arterial Hypertension Market

11.1.1 Overview

11.1.2 North America: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3 North America: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.1.4 North America: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.1.5 North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.6 North America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.1.6.1 US: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.1.1 Overview

11.1.6.1.2 US: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.1.3 US: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.1.6.1.4 US: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.1.6.1.5 US: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.6.1.6 US: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.1.6.2 Canada: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.2.1 Overview

11.1.6.2.2 Canada: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.2.3 Canada: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.1.6.2.4 Canada: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.1.6.2.5 Canada: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.6.2.6 Canada: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.1.6.3 Mexico: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.3.1 Overview

11.1.6.3.2 Mexico: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.6.3.3 Mexico: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.1.6.3.4 Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.1.6.3.5 Mexico: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.6.3.6 Mexico: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.2 Europe: Pulmonary Arterial Hypertension Market

11.2.1 Overview

11.2.2 Europe: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.3 Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.2.4 Europe: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.2.5 Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.2.6 Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.2.7 Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

11.2.7.1 UK: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.1.1 Overview

11.2.7.1.2 UK: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.1.3 UK: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.2.7.1.4 UK: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.2.7.1.5 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.2.7.1.6 UK: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.2.7.2 Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.2.1 Overview

11.2.7.2.2 Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.2.3 Germany: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.2.7.2.4 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.2.7.2.5 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.2.7.2.6 Germany: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.2.7.3 France: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.3.1 Overview

11.2.7.3.2 France: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.3.3 France: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.2.7.3.4 France: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.2.7.3.5 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.2.7.3.6 France: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.2.7.4 Italy: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.4.1 Overview

11.2.7.4.2 Italy: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.4.3 Italy: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.2.7.4.4 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.2.7.4.5 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.2.7.4.6 Italy: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.2.7.5 Spain: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.5.1 Overview

11.2.7.5.2 Spain: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.5.3 Spain: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.2.7.5.4 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.2.7.5.5 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.2.7.5.6 Spain: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.2.7.6 Rest of Europe: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.6.1 Overview

11.2.7.6.2 Rest of Europe: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.2.7.6.3 Rest of Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.2.7.6.4 Rest of Europe: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.2.7.6.5 Rest of Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.2.7.6.6 Rest of Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.3 Asia Pacific: Pulmonary Arterial Hypertension Market

11.3.1 Overview

11.3.2 Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.3 Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.3.4 Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.3.5 Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.3.6 Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.3.7 Asia Pacific: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

11.3.7.1 China: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.1.1 Overview

11.3.7.1.2 China: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.1.3 China: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.3.7.1.4 China: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.3.7.1.5 China Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.3.7.1.6 China Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.3.7.2 Japan: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.2.1 Overview

11.3.7.2.2 Japan: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.2.3 Japan: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.3.7.2.4 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.3.7.2.5 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.3.7.2.6 Japan: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.3.7.3 India: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.3.1 Overview

11.3.7.3.2 India: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.3.3 India: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.3.7.3.4 India: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.3.7.3.5 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.3.7.3.6 India: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.3.7.4 South Korea: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.4.1 Overview

11.3.7.4.2 South Korea: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.4.3 South Korea: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.3.7.4.4 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.3.7.4.5 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.3.7.4.6 South Korea: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.3.7.5 Australia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.5.1 Overview

11.3.7.5.2 Australia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.5.3 Australia: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.3.7.5.4 Australia: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.3.7.5.5 Australia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.3.7.5.6 Australia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.3.7.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.6.1 Overview

11.3.7.6.2 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.3.7.6.3 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.3.7.6.4 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.3.7.6.5 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.3.7.6.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.4 South and Central America Pulmonary Arterial Hypertension Market

11.4.1 Overview

11.4.2 South and Central America: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.4.3 South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.4.4 South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.4.5 South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.4.6 South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.4.7 South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

11.4.7.1 Brazil: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.4.7.1.1 Overview

11.4.7.1.2 Brazil: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.4.7.1.3 Brazil: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.4.7.1.4 Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.4.7.1.5 Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.4.7.1.6 Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.4.7.2 Argentina: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.4.7.2.1 Overview

11.4.7.2.2 Argentina: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.4.7.2.3 Argentina: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.4.7.2.4 Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.4.7.2.5 Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.4.7.2.6 Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.4.7.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.4.7.3.1 Overview

11.4.7.3.2 Rest of South and Central America: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.4.7.3.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.4.7.3.4 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.4.7.3.5 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.4.7.3.6 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.5 Middle East & Africa Pulmonary Arterial Hypertension Market

11.5.1 Overview

11.5.2 Middle East & Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

11.5.3 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.5.4 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.5.5 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.5.6 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.5.7 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

11.5.7.1 UAE: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)

11.5.7.1.1 Overview

11.5.7.1.2 UAE: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.5.7.1.3 UAE: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.5.7.1.4 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.5.7.1.5 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.5.7.1.6 UAE: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.5.7.2 Saudi Arabia: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)

11.5.7.2.1 Overview

11.5.7.2.2 Saudi Arabia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.5.7.2.3 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.5.7.2.4 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.5.7.2.5 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.5.7.2.6 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.5.7.3 South Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)

11.5.7.3.1 Overview

11.5.7.3.2 South Africa: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.5.7.3.3 South Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.5.7.3.4 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.5.7.3.5 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.5.7.3.6 South Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.5.7.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)

11.5.7.4.1 Overview

11.5.7.4.2 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.5.7.4.3 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.5.7.4.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.5.7.4.5 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.5.7.4.6 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

12. Impact Of COVID-19 Pandemic on Pulmonary Arterial Hypertension Market

12.1 North America: Impact Assessment of COVID-19 Pandemic

12.2 Europe: Impact Assessment of COVID-19 Pandemic

12.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic

12.4 South & Central America: Impact Assessment of COVID-19 Pandemic

12.5 Middle East & Africa: Impact Assessment of COVID-19 Pandemic

13. Pulmonary Arterial Hypertension Market – Industry Landscape

13.1 Overview

13.2 Growth Strategies in the Pulmonary Arterial Hypertension Market (%)

13.3 Organic Developments

13.3.1 Overview

13.4 Inorganic Developments

13.4.1 Overview

14. Company Profiles

14.1 Johnson & Johnson

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Gilead Sciences Inc

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 United Therapeutics Corp

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 Bayer AG

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 Aerami Therapeutics Holdings Inc

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Novartis AG

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 GSK Plc

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 Teva Pharmaceutical Industries Ltd

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 Lupin Ltd

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

14.10 Pfizer Inc

14.10.1 Key Facts

14.10.2 Business Description

14.10.3 Products and Services

14.10.4 Financial Overview

14.10.5 SWOT Analysis

14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners

15.2 Glossary of Terms

LIST OF TABLES.

Table 1. Drugs Patents Expiration Data

Table 2. North America Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 3. North America Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 4. North America Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 5. North America Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 6. US Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 7. US Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 8. US Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 9. US Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 10. Canada Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 11. Canada Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 12. Canada Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 13. Canada Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 14. Mexico Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 15. Mexico Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 16. Mexico Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 17. Mexico Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 18. Europe Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 19. Europe Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 20. Europe Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 21. Europe Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 22. UK Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 23. UK Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 24. UK Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 25. UK Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 26. Germany Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 27. Germany Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 28. Germany Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 29. Germany Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 30. France Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 31. France Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 32. France Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 33. France Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 34. Italy Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 35. Italy Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 36. Italy Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 37. Italy Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 38. Spain Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 39. Spain Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 40. Spain Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 41. Spain Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 42. Rest of Europe Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 43. Rest of Europe Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 44. Rest of Europe Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 45. Rest of Europe Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 46. Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 47. Asia Pacific Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 48. Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 49. Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 50. China Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 51. China Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 52. China Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 53. China Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 54. Japan Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 55. Japan Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 56. Japan Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 57. Japan Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 58. India Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 59. India Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 60. India Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 61. India Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 62. South Korea Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 63. South Korea Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 64. South Korea Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 65. South Korea Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 66. Australia Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 67. Australia Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 68. Australia Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 69. Australia Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 70. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 71. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 72. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 73. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 74. South and Central America: Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 75. South and Central America: Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 76. South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)

Table 77. South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

Table 78. Brazil: Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 79. Brazil: Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 80. Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)

Table 81. Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 82. Argentina: Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 83. Argentina: Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 84. Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)

Table 85. Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 86. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 87. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 88. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)

Table 89. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 90. Middle East & Africa Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 91. Middle East & Africa Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 92. Middle East & Africa Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 93. Middle East & Africa Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 94. UAE Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 95. UAE Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 96. UAE Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 97. UAE Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 98. Saudi Arabia Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 99. Saudi Arabia Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 100. Saudi Arabia Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 101. Saudi Arabia Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 102. South Africa Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 103. South Africa Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 104. South Africa Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 105. South Africa Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 106. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 107. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 108. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 109. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 110. Organic Developments in the Pulmonary Arterial Hypertension Market

Table 111. Inorganic Developments in the Pulmonary Arterial Hypertension Market

Table 112. Glossary of Terms

LIST OF FIGURES.

Figure 1. Pulmonary Arterial Hypertension Market Segmentation

Figure 2. Pulmonary Arterial Hypertension Market – By Geography

Figure 3. Pulmonary Arterial Hypertension Market Overview

Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of Pulmonary Arterial Hypertension Market

Figure 5. Asia Pacific to Show Significant Growth During Forecast Period

Figure 6. Pulmonary Arterial Hypertension Market, by Geography (US$ Million)

Figure 7. Global Pulmonary Arterial Hypertension Market – Leading Country Markets (US$ Million)

Figure 8. Global Pulmonary Arterial Hypertension Market, Industry Landscape

Figure 9. North America: PEST Analysis

Figure 10. Europe: PEST Analysis

Figure 11. Asia Pacific: PEST Analysis

Figure 12. Middle East and Africa: PEST Analysis

Figure 13. South and Central America: PEST Analysis

Figure 14. Experts Opinion

Figure 15. Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint

Figure 16. Global Pulmonary Arterial Hypertension Market– Revenue Forecast and Analysis – 2020 - 2028

Figure 17. Global Pulmonary Arterial Hypertension Market – By Geography Forecast and Analysis – 2022 - 2028

Figure 18. Market Positioning of Key Players in Pulmonary Arterial Hypertension Market

Figure 19. Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)

Figure 20. Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21. Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22. SGC Stimulators: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23. Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24. Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)

Figure 25. Branded: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26. Generics: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27. Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)

Figure 28. Oral: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29. Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30. Inhalational: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31. Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)

Figure 32. Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33. Online Pharmacies: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34. Retail Pharmacies: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 35. North America: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)

Figure 36. North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37. North America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

Figure 38. US: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 39. Canada: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 40. Mexico: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 41. Europe: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)

Figure 42. Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 43. Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

Figure 44. Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 45. Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 46. France: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 47. Italy: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 48. Spain: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 49. Rest of Europe: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 50. Asia Pacific: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)

Figure 51. Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 52. China: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 53. Japan: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 54. India: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 55. South Korea: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 56. Australia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 57. Rest of Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 58. South and Central America: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)

Figure 59. South and Central America Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Million)

Figure 60. South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

Figure 61. Brazil: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 62. Argentina: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 63. Rest of South and Central America: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 64. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)

Figure 65. Middle East & Africa Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (USD Million)

Figure 66. UAE: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 67. Saudi Arabia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 68. South Africa: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 69. Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 70. Impact of COVID-19 Pandemic in North America Country Markets

Figure 71. Impact of COVID-19 Pandemic in European Country Markets

Figure 72. Impact of COVID-19 Pandemic on Asia Pacific Country Markets

Figure 73. Impact of COVID-19 Pandemic in South and Central American Countries

Figure 74. Impact of COVID-19 Pandemic on Middle East and Africa Country Markets

Figure 75. Growth Strategies in the Pulmonary Arterial Hypertension Market (%)

The List of Companies - Butterfly Needles Market

• Johnson & Johnson

• Gilead Sciences Inc

• United Therapeutics Corp

• Bayer AG

• Aerami Therapeutics Holdings Inc

• Novartis AG

• GSK Plc

• Teva Pharmaceutical Industries Ltd

• Lupin Ltd

• Pfizer Inc

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the pulmonary arterial hypertension market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the global pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TOP